Bioporto secures patent in China
The Danish biotech company BioPorto has been issued a cut-off patent in China for a kidney test. The product is now patented in Europe and ten additional countries.
by Leonora Beck
A cut-off patent for BioPorto’s kidney test NGAL means that crucial IP rights for the product has now been secured in China, the company writes in a stock market release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
